UnitedHealth Group reported $14.4 billion in 2024 profits as its UnitedHealthcare health insurance and Optum provider services overcame rising costs and a cyberattack.

In his first public comments since one of his executives was shot to death, UnitedHealth Group CEO Andrew Witty said the healthcare system “needs to function better.”

UnitedHealth Group CEO Andrew Witty honored Brian Thompson, the health insurance executive murdered last month, praising his dedication to improving the U.S. health care system. Witty acknowledged public support following the tragedy and highlighted the nation’s costly health care as the root issue behind access and quality concerns.

UnitedHealth Group Inc (UNH) stock saw a decline, ending the day at $509.76 which represents a decrease of $-0.83 or -0.16% from the prior close of $510.59. The stock opened at $505.62 and touched a low of $502.

Q4 2024 Earnings Call Transcript January 16, 2025 UnitedHealth Group Incorporated beats earnings expectations. Reported EPS is $6.81, expectations were $6.74. Operator: Good morning, and welcome to UnitedHealth Group Fourth Quarter and Full Year 2024 Earnings Conference Call.

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.

CEO Andrew Witty promised that UnitedHealthcare would work to speed up turnaround times for approval of some procedures and services in Medicare Advantage plans.

UnitedHealth Group beat estimates for fourth quarter profit as the Eden Prairie, Minnesota-based health care giant released its first earnings report since the fatal ambush last month of top executive Brian Thompson in New York City.

UnitedHealth Group CEO Andrew Witty told analysts that the company is positioned well for growth in 2025. This comes just a month after the CEO of its insurance unit was murdered.

TD Cowen analyst Ryan Langston maintained a Buy rating on UnitedHealth (UNH – Research Report) yesterday and set a price target of

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.